Nuveen’s Telomir Pharmaceuticals TELO Stock Holding History

Nuveen’s Portfolio TELO Stock Details TELO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-24,990	Closed	-$80.7K	–	3434
2025 Q1	$80.7K	Hold	24,990	–	–	﹤0.01%	3232
2024 Q4	$103K	Buy	+24,990	New	+$118K	﹤0.01%	3288

Other funds holding TELO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

SEM

Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return

Nuveen's TELO Position: Q2 2025 in Review

Nuveen sold out of Telomir Pharmaceuticals (TELO) in Q2 2025, closing a stake of 24,990 shares — an estimated $80.7K sold.

Nuveen first reported a position in TELO in Q4 2024 and held it in 2 quarters. The position peaked at $103K in Q4 2024. 43 funds tracked by Wall St. Rank hold TELO as of Q2 2025.

Nuveen reported no remaining Telomir Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Nuveen sold 24,990 Telomir Pharmaceuticals shares in Q2 2025, an estimated $80.7K.
Nuveen first reported a position in Telomir Pharmaceuticals in Q4 2024 and held it in 2 quarters.
Nuveen's Telomir Pharmaceuticals position peaked at $103K in Q4 2024.
43 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.